Glaxosmithkline Plc's MAGRITi trial does not meet first co-primary endpoints

Thursday, 20 Mar 2014 03:00am EDT 

Glaxosmithkline Plc:Says an analysis of the MAGRITi trial, a Phase III trial of its MAGE-A3 cancer immunotherapeuticii in non-small cell lung cancer (NSCLC) patients, showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend disease-free survival (DFSiii).When compared to placebo in either the overall MAGE-A3 positive population (first co-primary endpoint) or in those MAGE-A3-positive patients who did not receive chemotherapy (second co-primary endpoint). 

Company Quote

0.02 +0.04%
21 Nov 2014